At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02561 VISEN PHARMA-B
Market Closed 10-23 16:08:08
15.200
-1.770
-10.43%
High16.470
Low15.100
Vol66.40K
Open16.470
D1 Closing16.970
Amplitude8.07%
Mkt Cap1.73B
Tradable Cap1.73B
Total Shares114.00M
T/O1.02M
T/O Rate0.06%
Tradable Shares114.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
VISEN PHARMA-B Reports Stable Capital Structure in September 2026 Monthly Return
Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.